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1. Economic Model  
 
1-1. Transition Between States 
 
With each annual time step of the model, the cohort is further divided between the 
model states based on transition probabilities. To demonstrate this concept, we can 
observe what happens to the portion of the cohort in the Susceptible, not immunized 
state (Figure 1-1).  
Each year, a certain percentage of that group will be vaccinated and distributed 
between the 95 Immune states (1, 2,…, 95 years to immunity loss) and the Susceptible, 
immunized state.  
Of those not vaccinated (in the Susceptible, not immunized state), a portion will be 
infected with HAV. Non-infected individuals will remain Susceptible, not immunized 
for the following cohort-year, while infected persons will transition into one of four 
states based on the probabilities of progression: Immune (due to disease), immunity 
unknown; Immune (due to disease), immunity known; 0 years since transplant; or 
Death. Individuals who develop fulminant Hepatitis and survive the year of a liver 
transplant progress to 0 years since transplant. All other who have icteric HAV that is 
identified and reported are moved to Immune (due to disease), immunity known. The 
rest of infected cases, which all have unreported anicteric or icteric HAV progress to 
Immune (due to disease), immunity unknown.  
After all of the above transitions have occurred, a percentage of the cohort in all 
states transitions to Death to account for non-HAV related deaths. This process is 
repeated in following years with the portion of individuals that remain Susceptible, 
not immunized. In the case of intervention models, the proportion of the birth cohort 
that received zero or one dose of HAV vaccination prior to age two, will be eligible to 
receive one or two additional doses of HAV vaccine in years 3 of 17 of the 
simulation.   
1-2: Health Outcomes 
The model estimates multiple outcomes of HAV including the number of:  
1) Cases of icteric and anicteric acute infections, HAV-related hospitalizations, 
acute liver failures, liver transplants and deaths. 
2) Childhood and adult immunizations  
3) Mild and severe adverse effects resulting from HAV immunizations 
4) Days of work loss and productivity losses due to: care-giving or self-care for 
HAV-related illness, HAV-related death, getting a HAV vaccination, and care-
giving or self-care for adverse effects resulting from HAV vaccination 
5) Costs of medical care of HAV-related illness, including outpatient visits and 
hospitalizations 
6) Childhood and adult HAV immunization costs 
7) Public health response costs  
8) Life years and QALYs: QALYs are calculated by weighting time spent in each 
health state by the state’s utility value and summing over an individual’s 
lifetime.  In line with standard health economic practice, QALY values assume  
that individual healthy state background QALYs decline with age due to the 
increasing prevalence of other health conditions  
2: Model Inputs: Data and Assumptions 
 
2.1: Inclusion of Epidemiologic Methods 
The health outcomes of interest were estimated using a rate-based multiplicative 
model of reported incidence rates for acute Hepatitis A infections, adjustments for 
under-reporting of acute cases, previous Hepatitis A vaccination rates among 
children <2 years of age, adolescents, and adults, transition probabilities between 
health states, and the effectiveness of HAV vaccination. The epidemiology of HAV 
incidence has changed dramatically since routine vaccination was recommended by 
ACIP in 2006, shifting from predominantly person-to-person transmission prior to 
the recommendation to infection from a contaminated source (such as imported 
food products).    To reflect this shift, unlike previous uses of the same model, 
incidence was assumed to be uniform across age groups.   
2.2: HAV Infection Clinical Characteristics and Disease Progression: 
 
The model assumes that infections can only occur among those in the cohort in the 
Susceptible, not immunized state who were not vaccinated in the current year or 
anyone in the Susceptible, immunized state who lost immunity before the current 
year. In the model, the probability of probability of icteric (symptomatic jaundice) 
disease given infection increased with age based on a previously published equation 
describing this relationship.19  
HAV disease development stages 
New infections are divided into icteric and anicteric (asymptomatic or mildly 
symptomatic without jaundice) cases as based on a published age-related function.19 
By assumption, the model classifies 50% of anicteric cases as asymptomatic, 25% as 
mildly symptomatic resulting in minor QALY losses but no health care utilization, 
and 25% as mildly symptomatic resulting in mild QALY losses and one outpatient 
visit.    Icteric cases are categorized as cases of moderate severity that utilize 
outpatient care, and high severity which require hospitalization.  Hospitalized cases 
have an age-specific probability of developing fulminant liver failure (FLF).  Those 
with FLF might resolve their infection and recover, die from their infection, or 
receive a transplant.  Those with transplants experience an annual probability of 
death from transplantation that declined by year following transplant.  Liver 
transplant recipients who die as a result of transplant-related causes in any year are 
considered to be deaths from HAV.   
HAV-related disease outcomes  
The model assumes that within each of the anicteric and icteric stages, patients 
require different degrees of healthcare.  The rationale underlying these assumptions 
are described in previous model documentation and publications.13,19 Asymptomatic 
anicteric cases do not require healthcare and are all unreported. Symptomatic 
anicteric cases are assumed to be relatively mild; only 50% of symptomatic anicteric 
HAV cases necessitate outpatient visits; of those, only 1 patient visit per person is 
assumed. All symptomatic anicteric cases are unreported. Icteric cases are either 
reported or unreported; the number of reported cases is calculated as the number of 
icteric cases divided by 2.95, which is the estimated number of total icteric cases per 
reported case.15 The model assumes 95% of all icteric cases require outpatient 
visits. All reported cases, by definition, are assumed to require healthcare, either 
outpatient visits or hospitalizations.  
 
All fulminant cases are assumed to require hospitalization. Not all fulminant cases 
receive a liver transplant; of those that do not, some die with a specified probability 
and the remaining recover. All fulminant cases receiving a transplant have a 
probability of death during and shortly after surgery, and one to 18 years after 







 Supplemental Table S-1. Hepatitis A model transition states 
State Description  
Susceptible, not immunized Never immunized and susceptible to infection  
Immune:1-95 years to 
immunity loss 
Immunized; vaccine immunity not (yet) lost. There are 95 states, one for each 
possible number of remaining years of immunity loss 
Susceptible, immunized 
Immunized; vaccine-induced immunity is lost and individual is susceptible to 
infection  
Immune (due to disease), 
immunity unknown  
Immune due to past disease. Disease was not identified, therefore immunity is not 
known and individual may seek vaccination   
Immune (due to disease), 
immunity known  
Immune due to past disease. Disease was identified and individual will not seek 
vaccination  
Immune (due to disease), also 
vaccinated  
Immune due to past disease. Disease was not identified and individual sought and 
received vaccination  
0-20+ years since liver 
transplant 
History of fulminant Hepatitis A which resulted in liver transplantation and 
subsequently in a reduced quality of life and increased risk of death. There are 21 
states, one for each number of possible years since transplant (20 or more years 
are grouped together)  
Death  
Death due to Hepatitis A or non-Hepatitis A related cases. Productivity losses 
accumulated throughout lifetime.  
Supplemental Table S-2. Reported cases and incidence of acute Hepatitis A by 
age and region in the United States, 2008-2012 
  Total  2008 2009 2010 2011 2012 
  Cases Incidence* Cases Incidence* Cases Incidence* Cases Incidence* Cases Incidence* Cases Incidence* 
Total  9,202 0.58 2,585 0.85 1,987 0.65 1,670 0.54 1,398 0.45 1,562 0.5 
Age-group                         
0 - 9 599 0.29 210 0.51 130 0.31 125 0.31 72 0.18 62 0.15 
10-19 1107 0.53 322 0.78 236 0.57 209 0.49 172 0.41 168 0.40 
20 - 29  1777 0.83 436 1.03 413 0.96 347 0.81 279 0.64 302 0.69 
30 - 39  1340 0.66 382 0.94 311 0.77 234 0.58 206 0.51 207 0.51 
40 - 49  1223 0.56 380 0.86 273 0.62 201 0.46 168 0.39 201 0.47 
50 - 59  1185 0.57 344 0.86 223 0.55 196 0.47 181 0.42 241 0.56 
60+  1863 0.66 496 0.92 375 0.68 335 0.59 298 0.5 359 0.59 
Missing 108 --- 15 --- 26 --- 23 --- 22 --- 22 --- 
Region                          
New England 491 0.68 128 0.89 108 0.75 95 0.66 77 0.53 83 0.57 
Mid. Atlantic  1369 0.67 333 0.82 275 0.67 276 0.68 252 0.61 233 0.57 
E.N. Central  1271 0.55 335 0.72 284 0.61 203 0.44 214 0.46 235 0.50 
W. N. Central  631 0.62 255 1.26 126 0.62 102 0.50 59 0.29 89 0.43 
S. Atlantic 1662 0.56 393 0.68 429 0.72 351 0.59 222 0.37 267 0.44 
E. S. Central  301 0.33 81 0.45 46 0.25 48 0.26 48 0.26 78 0.42 
W. S. Central  979 0.54 294 0.83 209 0.58 158 0.43 157 0.42 161 0.43 
Mountain  818 0.74 219 1.01 163 0.74 144 0.65 129 0.58 163 0.72 
Pacific  1680 0.68 547 1.11 347 0.70 293 0.59 240 0.48 253 0.50 
*Rate per 100,000 
Table S-3 Parameters of Hepatitis A-disease progression 
Parameter Value  Source 
Clinical characteristics and symptoms     
  Probability of Icteric Infection by age 
    0-4 years of age 0.072 
19 
 
5-9 years of age 0.371  
10-17 years of age 0.707  
≥18 years of age 0.852  
  Probability of symptoms | anicteric HAV infection 0.50   Assumption 
  Total number of icteric cases per reported case 1.95 15  
Progression of disease and healthcare    
  Probability of outpatient visit and work loss |symptomatic anicteric infection    0.50 Assumption 
  Probability of receiving any level of medical care | icteric HAV infection  0.95 25 
  Probability of hospitalization | reported icteric HAV infection     
All ages   0.427  
    <18 years of age 0.243 
16 
18-39 years of age 0.450 
40-64 years of age 0.662 
≥65 years of age 0.625 
   Probability of fulminant HAV | reported icteric HAV infection     
        0-9 years of age  0.0038 39  





15-39 years of age 0.0068 
40-59 years of age 0.055 
60-95 years of age   0.08 
Probability of receiving liver transplant | Fulminant 0.65 
Probability of death from Fulminant | no liver transplant 0.14 20 
Annual Probability of death | liver transplant    
             0-1 year  0.184 40 
1-3 years 0.03               
40 
4-18 years  0.015          
   
  
Supplemental Table S-4. HAV vaccination adverse events, and costs* 
Parameter Value Source 
Adverse Events    
Probability of mild adverse event (all ages)  0.0051 41 
Probability of severe adverse event (all ages) 0.000001 42 
Severe adverse event (medical care costs - all ages) $56,046.38 43 
Direct Costs   
Proportion of vaccines purchased at public price    
ages 0-17 years 0.55 Personal 
Communication, 
GSK ages 18-95 years 
0.05 
Acquisition cost    
Public   
ages 0-17 years $17.01 
44,45 
ages 18-95 years $25.73 
Private   
ages 0-17 years $28.74 
ages 18-95 years $63.72 
Administration cost ages 2-11, 13-64 $14.00 46 
Administration cost age 12† $7.00  
Indirect costs   
Productivity   
Work days lost    
HAV vaccination     
age 0-12 years  0 
13 
age 13-95 years  0.125 
Mild adverse event (all ages) 0.875 
Severe adverse event (all ages) 5 
*All costs reflect 2015 $U.S. value  
†At age 12, administration costs are $7.00 due to shared administration costs with other 
routine vaccines.  
 Supplemental Table S-5. Direct and indirect costs of Hepatitis A infection 
Parameter Value  Source  
Direct costs     
Medical      
Number of outpatient visits for symptomatic anicteric HAV infection  1 Assumption 
Outpatient cost for symptomatic anicteric HAV infection  $104.12  24 
Number of outpatient visits for symptomatic icteric HAV infection  3 26 
Outpatient costs of non-fulminant reported icteric HAV infection  $1,016  
25,26,28 
Inpatient costs of non-fulminant reported icteric HAV infection  $10,035  
Inpatient Cost of fulminant HAV with liver transplant     
Year of transplant $353,715  29 
Years after transplant (1-18 years) $31,670  26 
Inpatient Cost of fulminant HAV without liver transplant  $29,864  26 
Percent reduction in medical costs for unreported versus reported icteric HAV 
infection  
0.333 13 
Indirect costs    
Productivity   
Probability of work loss and no medical care | symptomatic anicteric HAV infection  0.5 Assumption 
Work days lost    
Symptomatic anicteric infection  3 Assumption 
Non-hospitalized icteric infection    
Reported   
Ages 0-12 years 3.7 47 
Ages 13-95 years  10  
Unreported  3 Assumption 
Hospitalization - icteric infection  33.2 
26 Hospitalization - fulminant Hepatitis / no liver transplant  33.2 
Liver transplant - per year 153.2 
Costs of productivity loss    
Daily cost of work loss    
Ages 0-15 years $120.20  30 
Ages 16-19 years $63.42  Assumption 
Ages 20-24 years $83.40  
30 
Ages 25-34 years $121.53  
Ages 35-44 years $143.15  
Ages 45-54 years $146.41  
Ages 55-64 years $146.61  
Ages 65-95 years $105.02  
Labor force participation rate   
Ages 0-15 years 0.815* 
48 
Ages 16-19 years 0.343 
Ages 20-24 years 0.709 
Ages 25-34 years 0.817 





Ages 35-44 years 0.826 
Ages 45-54 years 0.802 
Ages 55-64 years 0.645 
Ages 65-74 years 0.268 
Ages 75 and older 0.076 
*Labor participation rate, daily earnings of parent or caregiver (calculated as a weighted average of 20 to 44-year-olds). 
Parameter Value  Source  
Public health response    
General    
Mean hourly wage for licensed practical or licensed vocational nurse  $21.3  49 
Proportion of reported cases with follow-up by PHA 0.55 
13 
Surveillance   
Probability of phone call by PHA to the infected patient's physician  1 
Length of time (hours), phone all by PHA to the infected patient's physician 1 
Probability of phone call by PHA to the infected patient | physician phone call  0.8 
Length of time (hours), phone all by PHA to the infected patient 1 
Probability of visit by PHA to the infected patient | physician and patient phone  0.25 
Length of time (hours), visit by PHA to the infected patient  4 
IG coordination and administration     
IG cost per dose $23.52  
13 
Proportion of cases with follow-up for whom IG shots for contacts are coordinated by PHA 1 
Proportion of reported cases, FSW 0.06 
No. phone calls to contacts, FSW cases with follow-up  73 
No. phone calls to contacts, all other cases with follow-up   25 
Length (hours) of phone calls to contacts 1 
No. IG shots to contacts, FSW cases with follow-up  29 
No. IG shots to contacts, all other cases with follow-up 10 
Length (hours) for coordination of IG shots for contacts  4 
Public notification    
Proportion of reported cases for whom visit made to employer (FSW cases only) 0.02 
13 
Length (hours) employer visit (FSW cases only)  8 
Proportion of reported cases for whom a public notification is made 0.002 
Length (hours) for PHS to make public notification  160 
IG: immunoglobulin; PHA: public health authority; FSW: food service workers 
Supplemental Table S-7. Quality Adjusted Life Years associated with HAV 
infection 
Parameter Value  Source  
Duration of sickness (days)     
Symptomatic anicteric HAV infection  3 Assumption  
Non-hospitalized icteric HAV infection  34.4 
26 
Hospitalization*  67.8 
QALY value    
Healthy    
ages 0-4 years 0.94 
49 
ages 5-17 years 0.93 
ages 18-34 years 0.915 
ages 35-44 years 0.895 
ages 45-54 years 0.865 
ages 55-64 years 0.805 
ages 65-74 years 0.77 
ages 75-95 years 0.695 
Annual QALY decrement    
Symptomatic anicteric HAV infection   
31 
*Jacobs, et al (2002)  0.007 
GBD (Model Baseline) 0.005 
Non-hospitalized icteric HAV infection   
*Jacobs, et al (2002)  0.039 
GBD (Model Baseline) 0.053 
Hospitalization**  
*Jacobs, et al (2002)  0.076 
GBD (Model Baseline) 0.21 
* Provided for comparison purposes only 
**Includes fulminant, and pre- and post-transplant Hepatitis A infection 
GBD: global burden of disease 
 
Supplemental Table S-8: Variables and Values Used in Univariate Sensitivity 
Analyses Threshold Analyses 
 
Category Variable Baseline Low High Comments 
Coverage 
Catchup, 1st dose | 
Never Vaccinated 0.500 0.375 0.625 ±25% 
Costs 
Child Vaccine 
Purchase Cost - 
Public $16.18 $12.14 $20.23 ±25% 
 
Child Vaccine 
Purchase Cost - 
Private $31.49 $23.62 $39.36 ±25% 
 Percentage of Child 
Vaccine Purchased 
at the Public Price 0.550 0.413 0.688 ±25% 
 
Annual Rate of Adult 
Vaccination 0.005 0.0038 0.0063 ±25% 
Risk Incidence 1 per 100,000 n/a 
Threshold 
analysis 
Model could not calculate 
incidence lower than 1 
per 100,000 
    
From 1.5 to 
12.0 per 
100,000  
Health Impacts   QALY Decrements    
Low combines the lowest 
values published across 
Jacobs, et al (2007) and 
the Salomon, et al 
(2012), high combines 
the highest. 
 Mild 0.005 0.005 0.007 
 Moderate 0.053 0.039 0.053 
 Severe 0.210 0.076 0.210 
Effectiveness 
Rate of Decline in 
Antibody Titers    
Low combines the lowest 
values published across 
Rein, et al (2007) and the 
new analysis conducted 
for this study. High 
combines the highest 
values. 
 Years 1-4 0.166 0.166 0.200 
 Years 5-9 0.650 0.050 0.650 
 Years 10+ 0.054 0.050 0.540 
Value of Future 
Benefits Discount Rate 0.030 0.000 0.050 Standard range 
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